GoodRx Holdings Statistics
Total Valuation
GoodRx Holdings has a market cap or net worth of $1.15 billion. The enterprise value is $1.40 billion.
| Market Cap | 1.15B |
| Enterprise Value | 1.40B |
Important Dates
The next estimated earnings date is Tuesday, November 3, 2026, after market close.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GoodRx Holdings has 341.15 million shares outstanding. The number of shares has decreased by -9.06% in one year.
| Current Share Class | 107.18M |
| Shares Outstanding | 341.15M |
| Shares Change (YoY) | -9.06% |
| Shares Change (QoQ) | +1.94% |
| Owned by Insiders (%) | 3.94% |
| Owned by Institutions (%) | 17.73% |
| Float | 93.96M |
Valuation Ratios
The trailing PE ratio is 71.21 and the forward PE ratio is 31.30.
| PE Ratio | 71.21 |
| Forward PE | 31.30 |
| PS Ratio | 1.47 |
| Forward PS | 1.42 |
| PB Ratio | 1.78 |
| P/TBV Ratio | 61.61 |
| P/FCF Ratio | 5.85 |
| P/OCF Ratio | 5.72 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.83, with an EV/FCF ratio of 7.08.
| EV / Earnings | 85.91 |
| EV / Sales | 1.78 |
| EV / EBITDA | 12.83 |
| EV / EBIT | 15.64 |
| EV / FCF | 7.08 |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.83.
| Current Ratio | 1.38 |
| Quick Ratio | 0.42 |
| Debt / Equity | 0.83 |
| Debt / EBITDA | 4.60 |
| Debt / FCF | 2.73 |
| Interest Coverage | 2.19 |
Financial Efficiency
Return on equity (ROE) is 2.52% and return on invested capital (ROIC) is 3.85%.
| Return on Equity (ROE) | 2.52% |
| Return on Assets (ROA) | 3.05% |
| Return on Invested Capital (ROIC) | 3.85% |
| Return on Capital Employed (ROCE) | 7.53% |
| Weighted Average Cost of Capital (WACC) | 9.83% |
| Revenue Per Employee | $1.13M |
| Profits Per Employee | $23,313 |
| Employee Count | 697 |
| Asset Turnover | 0.43 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GoodRx Holdings has paid $25.15 million in taxes.
| Income Tax | 25.15M |
| Effective Tax Rate | 60.75% |
Stock Price Statistics
The stock price has decreased by -17.56% in the last 52 weeks. The beta is 1.60, so GoodRx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 1.60 |
| 52-Week Price Change | -17.56% |
| 50-Day Moving Average | 3.37 |
| 200-Day Moving Average | 2.72 |
| Relative Strength Index (RSI) | 46.96 |
| Average Volume (20 Days) | 1,216,628 |
Short Selling Information
The latest short interest is 4.35 million, so 1.28% of the outstanding shares have been sold short.
| Short Interest | 4.35M |
| Short Previous Month | 5.09M |
| Short % of Shares Out | 1.28% |
| Short % of Float | 4.63% |
| Short Ratio (days to cover) | 2.32 |
Income Statement
In the last 12 months, GoodRx Holdings had revenue of $785.23 million and earned $16.25 million in profits. Earnings per share was $0.05.
| Revenue | 785.23M |
| Gross Profit | 713.19M |
| Operating Income | 89.24M |
| Pretax Income | 41.40M |
| Net Income | 16.25M |
| EBITDA | 108.78M |
| EBIT | 89.24M |
| Earnings Per Share (EPS) | $0.05 |
Balance Sheet
The company has $296.11 million in cash and $538.95 million in debt, with a net cash position of -$242.84 million or -$0.71 per share.
| Cash & Cash Equivalents | 296.11M |
| Total Debt | 538.95M |
| Net Cash | -242.84M |
| Net Cash Per Share | -$0.71 |
| Equity (Book Value) | 647.60M |
| Book Value Per Share | 1.90 |
| Working Capital | 441.46M |
Cash Flow
In the last 12 months, operating cash flow was $201.58 million and capital expenditures -$4.49 million, giving a free cash flow of $197.09 million.
| Operating Cash Flow | 201.58M |
| Capital Expenditures | -4.49M |
| Depreciation & Amortization | 19.54M |
| Net Borrowing | -5.00M |
| Free Cash Flow | 197.09M |
| FCF Per Share | $0.58 |
Margins
Gross margin is 90.83%, with operating and profit margins of 11.36% and 2.07%.
| Gross Margin | 90.83% |
| Operating Margin | 11.36% |
| Pretax Margin | 5.27% |
| Profit Margin | 2.07% |
| EBITDA Margin | 13.85% |
| EBIT Margin | 11.36% |
| FCF Margin | 25.10% |
Dividends & Yields
GoodRx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 9.06% |
| Shareholder Yield | 9.06% |
| Earnings Yield | 1.41% |
| FCF Yield | 17.09% |
Analyst Forecast
The average price target for GoodRx Holdings is $4.03, which is 19.23% higher than the current price. The consensus rating is "Hold".
| Price Target | $4.03 |
| Price Target Difference | 19.23% |
| Analyst Consensus | Hold |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 4.04% |
| EPS Growth Forecast (3Y) | 6.46% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GoodRx Holdings has an Altman Z-Score of 0.24 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.24 |
| Piotroski F-Score | 5 |